Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Clearside Biomedical, Inc. CLSD
$1.05
-$0.03 (-2.78%)
На 18:00, 12 мая 2023
Ранг: 1
Ключевые показатели
-
Marketcap
64132744.00000000
-
week52high
1.86
-
week52low
0.90
-
Revenue
1327000
-
P/E TTM
-2
-
Beta
2.08096800
-
EPS
-0.53000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 10 авг 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 11 мар 2022 г. |
| HC Wainwright & Co. | Buy | 29 июл 2021 г. | |
| Wedbush | Outperform | Outperform | 17 июн 2021 г. |
| JMP Securities | Market Outperform | Market Outperform | 15 июн 2021 г. |
| Stifel | Buy | Hold | 10 ноя 2022 г. |
| Needham | Buy | Hold | 10 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 10 ноя 2022 г. |
| Needham | Buy | 03 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ciulla Thomas | D | 291890 | 13700 | 20 янв 2023 г. |
| Deignan Charles A. | D | 363472 | 14030 | 19 янв 2023 г. |
| LASEZKAY GEORGE M | D | 484577 | 20030 | 19 янв 2023 г. |
| Ciulla Thomas | D | 305590 | 2170 | 10 янв 2023 г. |
| Ciulla Thomas | A | 187500 | 187500 | 04 янв 2023 г. |
| Deignan Charles A. | A | 187500 | 187500 | 04 янв 2023 г. |
| LASEZKAY GEORGE M | A | 487500 | 487500 | 04 янв 2023 г. |
| Ciulla Thomas | A | 307760 | 5000 | 31 дек 2022 г. |
| Thorp Clay | A | 30522 | 14000 | 21 дек 2022 г. |
| Deignan Charles A. | D | 0 | 23636 | 20 дек 2022 г. |
Новостная лента
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 09:56
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.13 per share a year ago.
Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023
GlobeNewsWire
02 мая 2023 г. в 07:05
ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.
Clearside Biomedical, Inc. (CLSD) Q4 2022 Earnings Call Transcript
Seeking Alpha
09 мар 2023 г. в 20:22
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Charles Deignan - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Jonathan Wolleben - JMP Securities Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by and welcome to the Clearside Biomedical Fourth Quarter 2022 Financial Results and Corporate Update Conference Call.
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мар 2023 г. в 19:49
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023
GlobeNewsWire
23 февр 2023 г. в 07:05
ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.